REFERENCES
- Levenson JL. Neuroleptic malignant syndrome. Am J Psych 1985; 142: 1137–1145, [CSA]
- Eiser AR, Neff MS, Slifkin RF. Acute myoglobinuric renal failure—a consequence of the neuroleptic malignant syndrome. Arch Intern Med 1982; 142: 601–603, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Greenblatt DJ, Gross PL, Harris J, Shader RI, Ciraulo DA. Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal. J Clin Psych 1978; 38: 673–675, [CSA]
- Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003; 107: 45–49, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shalev A, Munita H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337–347, [PUBMED], [INFOTRIEVE], [CSA]
- Caroff SN. The neuroleptic malignant syndrome. J Clin Psych 1980; 41: 79–83, [CSA]
- Kurlan R, Hammii R, Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol 1984; 7: 109–120, [PUBMED], [INFOTRIEVE], [CSA]
- Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psych 1987; 22: 1004–1020, [CSA], [CROSSREF]
- Delay J, Pichot P, Lemperiere T. Un neuroleptique majeur non phenothiazinique et non reserpinique, I’ haloperidol, dans le traitement des psychoses. Ann Med Psych 1960; 118: 145–152, [CSA]
- Taniguchi N, Tanii H, Nishikawa T, et al. Classification system of complication in neuroleptic malignant syndrome. Meth Find Exp Clin Pharmacol 1997; 19: 193–199, [CSA]
- Lev R, Clark R. Neuroleptic malignant syndrome presenting without fever: case report and review of the literature. J Emerg Med 1994; 12: 49–55, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Soejima A, Suzuki M, Ishizuka S, et al. Clinical investigation of 10 cases with acute renal failure induced by neuroleptics. Jpn J Nephol 1996; 38: 335–341, (in Japanese)[CSA]
- Kunishima Y, Masumori N, Kadono M, Tsukamoto T. A case of neuroleptic malignant syndrome in a patient with hemodialysis. Inter J Uro 2000; 7: 62–64, [CSA], [CROSSREF]
- Nishimura M. Treatment of neuroleptic malignant syndrome with direct hemoperfusion. Biomat Art Cells Immnob Biotech 1991; 19: 175–183, [CSA]
- Toru M, Matsuda O, Makiguchi K, Sugano K. Neuroleptic malignant syndrome-like state following a withdrawal of anti-Parkinsonian drugs. J Nerv Ment Dis 1981; 169: 324–327, [PUBMED], [INFOTRIEVE], [CSA]
- Imaeda M, Sakai M, Misugi N, Fujiwara T. “Syndrome malin” due to neuroleptics—clinical and muscle studies of three cases. Yokohama Med Bull 1981; 32: 57–69, [CSA]
- Shalev A, Hermesh H, Munita H. Mortality from neuroleptic malignant syndrome. J Clin Psych 1989; 50: 18–25, [CSA]
- Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever. Arch Gen Psych 1986; 43: 839–848, [CSA]
- Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986; 6: 257–273, [PUBMED], [INFOTRIEVE], [CSA]
- Kellam AMP. The neuroleptic malignant syndrome, so-called a survey of the world literature. Br J Psych 1987; 150: 752–759, [CSA]
- Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin of North Am 2000; 18: 317–325, [CSA], [CROSSREF]
- Nishioka Y, Miyazaki M, Kub S, Ozono Y, Harada T, Kohno S. Acute renal failure in neuroleptic malignant syndrome. Renal Fail 2002; 24: 539–543, [CSA], [CROSSREF]